Healthcare - Medical - Instruments & Supplies - NASDAQ - BE
$ 8.22
-0.725 %
$ 282 M
Market Cap
-4.52
P/E
CASH FLOW STATEMENT
-44.8 M
OPERATING CASH FLOW
32 M
INVESTING CASH FLOW
16.9 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nyxoah S.A.
| Net Income | -44.7 M |
| Depreciation & Amortization | 2.36 M |
| Capital Expenditures | -11 M |
| Stock-Based Compensation | 2.61 M |
| Change in Working Capital | -3.49 M |
| Others | -1.6 M |
| Free Cash Flow | -55.7 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (44.7) | (30.1) | (24.6) | (12.2) | (7.2) | (9.0) | (10.3) |
| Depreciation & Amortization | 2.4 | 1.9 | 1.7 | 0.6 | 0.4 | 95 K | 87 K |
| Deferred Income Tax | 0 | 0 | (0.3) | (0.2) | 56 K | 76 K | 78 K |
| Stock Based Compensation | 2.6 | 2.7 | 1.3 | 2.5 | 0.3 | 28 K | 24 K |
| Other Operating Activities | (1.6) | (3.4) | (2.2) | 0.8 | 0.7 | 0.7 | 2.5 |
| Change in Working Capital | (3.5) | 86 K | (1.1) | 1.4 | (0.2) | 0.2 | (0.5) |
| Cash From Operations | (44.8) | (28.8) | (25.3) | (7.0) | (6.0) | (8.1) | (8.3) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (11.0) | (16.3) | (11.8) | (10.7) | (5.8) | 77 K | 91 K |
| Other Items | 43.0 | (73.6) | 0 | 13 K | 10 K | 2 K | 0 |
| Cash From Investing Activities | 32.0 | (89.9) | (11.8) | (10.7) | (5.8) | 75 K | 91 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (1.2) | (1.1) | (0.9) | 0.6 | 0.7 | 0 | 1.1 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.2) | (0.2) | (0.4) | (0.2) | 33 K | 0 | 0 |
| Cash From Financing Activities | 16.9 | (1.0) | 76.5 | 104.2 | 0.7 | 15.0 | 1.1 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 3.7 | (117.6) | 43.2 | 86.4 | (10.9) | 6.7 | (7.3) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (55.7) | (45.1) | (37.2) | (17.7) | (11.8) | (8.2) | (8.4) |